| TH2/TH1 shift under ibrutinib treatment in chronic lymphocytic leukemia MC Puzzolo, I Del Giudice, N Peragine, P Mariglia, MS De Propris, ... Frontiers in oncology 11, 637186, 2021 | 24 | 2021 |
| Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations S Raponi, C Ilari, I Della Starza, LV Cappelli, L Cafforio, A Piciocchi, ... British Journal of Haematology 189 (5), 853-859, 2020 | 19 | 2020 |
| Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study GM Rigolin, I Del Giudice, A Bardi, A Melandri, RE García-Jacobo, F Cura, ... Blood, The Journal of the American Society of Hematology 138 (25), 2727-2730, 2021 | 12 | 2021 |
| Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study I Innocenti, G Reda, A Visentin, M Coscia, M Motta, R Murru, R Moia, ... Haematologica 107 (6), 1470, 2022 | 11 | 2022 |
| Clinical relevance of-limit of detection (LOD)-limit of quantification (LOQ)-based flow cytometry approach for measurable residual disease (MRD) assessment in acute myeloid … R Palmieri, A Piciocchi, V Arena, L Maurillo, MI Del Principe, G Paterno, ... Blood 136, 37-38, 2020 | 10 | 2020 |
| Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group GM Rigolin, F Cavazzini, A Piciocchi, V Arena, A Visentin, G Reda, ... Hematological Oncology 39 (3), 326-335, 2021 | 9 | 2021 |
| Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid … F Buccisano, R Palmieri, A Piciocchi, V Arena, L Maurillo, MI Del Principe, ... Haematologica 107 (12), 2823, 2022 | 6 | 2022 |
| Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia L Cafforio, S Raponi, LV Cappelli, C Ilari, R Soscia, MS De Propris, ... haematologica 107 (1), 334, 2022 | 6 | 2022 |
| Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients—a 25‐year Italian experience. AM Testi, S Mohamed, D Diverio, A Piciocchi, G Menna, C Rizzari, ... British Journal of Haematology 195 (2), 2021 | 5 | 2021 |
| Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph-B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial S Chiaretti, I Della Starza, A Santoro, O Spinelli, L Elia, MS De Propris, ... Blood 142, 826, 2023 | 3 | 2023 |
| High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and … FR Mauro, I Della Starza, M Messina, G Reda, L Trentin, M Coscia, ... Haematologica 108 (8), 2091, 2023 | 3 | 2023 |
| ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol F Buccisano, R Palmieri, A Piciocchi, V Arena, A Candoni, L Melillo, ... Blood Advances 6 (8), 2510-2516, 2022 | 3 | 2022 |
| ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings S Chiaretti, A Taherinasab, I Della Starza, M Canichella, M Ansuinelli, ... Leukemia & Lymphoma 64 (2), 483-486, 2023 | 2 | 2023 |
| CD34+ CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia R Palmieri, F Buccisano, V Arena, MA Irno Consalvo, A Piciocchi, ... Leukemia & Lymphoma 63 (4), 996-1000, 2022 | 2 | 2022 |
| Results of the 6-year follow-up of the gimema AML1310 trial: a risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia A Venditti, A Piciocchi, R Palmieri, V Arena, A Candoni, V Calafiore, ... Blood 138 (Supplement 1), 2359-2359, 2021 | 2 | 2021 |
| 36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an … FR Mauro, I Della Starza, M Messina, G Reda, L Trentin, M Coscia, ... Blood 142, 1905, 2023 | 1 | 2023 |
| Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the … G Marconi, A Piciocchi, E Audisio, C Papayannidis, F Guolo, M Cerrano, ... Blood 142 (Supplement 1), 1536-1536, 2023 | 1 | 2023 |
| Peripherally inserted central venous catheter for pediatric acute Leukemia: a retrospective 11-year single-center experience S Ligia, SG Morano, F Kaiser, A Micozzi, A Chistolini, W Barberi, V Arena, ... The Journal of Vascular Access, 11297298231185222, 2023 | 1 | 2023 |
| Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation AM Testi, MF Al-Jadiry, HH Ghali, SA Fadhil, AF Al-Darraji, RM Al-Saeed, ... Leukemia & Lymphoma 63 (12), 2940-2947, 2022 | 1 | 2022 |
| Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol M Messina, A Piciocchi, T Ottone, S Paolini, C Papayannidis, F Lessi, ... Cancers 14 (12), 3012, 2022 | 1 | 2022 |
Alfonso PiciocchiGIMEMA Foundation, RomeVerified email at gimema.it
